PD-L1 Inhibition With MPDL3280A for Solid Tumors

Seminars in Oncology

Volumn 42, Issue 3, 2015, Pages 484-487

  Cha, Edward ^a   Wallin, Jeffrey ^a   Kowanetz, Marcin ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOCETAXEL; GAMMA INTERFERON; HLA DR ANTIGEN; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MPDL 3280A; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; SUNITINIB; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELLULAR IMMUNITY; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; DRUG DOSE ESCALATION; DRUG SAFETY; HUMAN; IMMUNOHISTOCHEMISTRY; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID TUMOR; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; DRUG POTENTIATION; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; DRUG SYNERGISM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84929148767     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.02.002     Document Type: Review

References (18)

1. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
2. C. Robert, L. Thomas, and I. Bondarenko Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
3. D.S. Chen, B.A. Irving, and F.S. Hodi Molecular pathways: next-generation immunotherapy - inhibiting programmed death-ligand 1 and programmed death-1 Clin Cancer Res 18 2012 6580 6587
4. D.S. Chen, and I. Mellman Oncology meets immunology: the cancer-immunity cycle Immunity 39 2013 1 10
5. W. Zou, and L. Chen Inhibitory B7-family molecules in the tumour microenvironment Nat Rev Immunol 8 2008 467 477
6. J.A. Brown, D.M. Dorfman, and F.R. Ma Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production J Immunol 170 2003 1257 1266
7. G.J. Freeman, A.J. Long, and Y. Iwai Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 2000 1027 1034
8. M.J. Butte, M.E. Keir, T.B. Phamduy, A.H. Sharpe, and G.J. Freeman Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses Immunity 27 2007 111 122
9. M. Warncke, T. Calzascia, and M. Coulot Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment J Immunol 188 2012 4405 4411
10. R.S. Herbst, J.C. Soria, and M. Kowanetz Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 2014 563 567
11. T. Powles, J.P. Eder, and G.D. Fine MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 2014 558 562
12. F.S. Hodi, H.M. Kluger, and R.J. Sullivan Clinical activity of the PD-L1 inhibitor MPDL3280A in patients with metastatic melanoma: updated phase I data [abstract] Pigment Cell Melanoma Res (Meeting Abstracts) 27 2014 1169
13. J.M. Taube, R.A. Anders, and G.D. Young Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape Sci Transl Med 4 2012 127ra37
14. T.F. Gajewski, H. Schreiber, and Y.X. Fu Innate and adaptive immune cells in the tumor microenvironment Nat Immunol 14 2013 1014 1022
15. Y. Latchman, C.R. Wood, and T. Chernova PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nat Immunol 2 2001 261 268
16. S.Y. Tseng, M. Otsuji, and K. Gorski B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells J Exp Med 193 2001 839 846
17. C. Lieu, J. Bendell, and J.D. Powderly Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or chemotherapy (chemo) in patients (pts) with locally advanced or metastatic solid tumors. [abstract] Ann Oncol (Meeting Abstracts) 25 2014 7069
18. D.F. McDermott, M. Sznol, and J.A. Sosman Immune correlates and long-term follow-up of a phase Ia study of MPDL328A, an engineered PD-L1 antibody, in patients with metastatic renal cell carcinoma (mRCC) [abstract] Ann Oncol (Meeting Abstracts) 25 2014 7090